Advanced search
Publication Cover
Scandinavian Journal of Gastroenterology Volume 55, 2020 - Issue 11
Submit an article Journal homepage
271
Views
5
CrossRef citations to date
0
Altmetric
Original Article

Efficacy and safety profile of calcineurin inhibitor salvage therapy in autoimmune hepatitis

Stuart K. Robertsa The Alfred Hospital, Melbourne, Australia;b Monash University, Melbourne, AustraliaCorrespondence[email protected]
,
Simone I. Strasserc Royal Prince Alfred Hospital, Sydney, Australia;d University of Sydney, Sydney, Australia
,
Amanda J. Nicollb Monash University, Melbourne, Australia;e Eastern Health, Melbourne, Australia
,
William Kempa The Alfred Hospital, Melbourne, Australia;b Monash University, Melbourne, Australia
,
Ammar Majeeda The Alfred Hospital, Melbourne, Australia;b Monash University, Melbourne, Australia
,
Joanne Mitchella The Alfred Hospital, Melbourne, Australia
,
Katherine Stuartf Princess Alexandra Hospital, Brisbane, Australia
,
Paul Gowg Austin Hospital, Melbourne, Australia
,
Siddharth Soodh Royal Melbourne Hospital, Melbourne, Australia
,
Gerry MacQuillani Sir Charles Gairdner Hospital, Perth, Australia
,
Jacob Georged University of Sydney, Sydney, Australia;j Storr Liver Centre, Westmead Institute for Medical Research, Westmead Hospital, Sydney, Australia
,
Jonathan Mitchellk Sunshine Coast General Hospital, Nambour, Australia
,
Geoffrey W. McCaughanc Royal Prince Alfred Hospital, Sydney, Australia;l Centenary Research Institute, Sydney, Australia
& on behalf of the ALA Clinical Research Network show all
Pages 1309-1317 | Received 30 Jun 2020, Accepted 01 Sep 2020, Published online: 17 Oct 2020

References

  • Krawitt EL. Autoimmune hepatitis. N Engl J Med. 2006;354(1):54–66.
  • Manns MP, Czaja AJ, Gorham JD, et al. Diagnosis and management of autoimmune hepatitis. Hepatology. 2010;51(6):2193–2131.
  • Manns MP, Woynarowski M, Kreisel W, et al. Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis. Gastroenterology. 2010;139(4):1198–1206.
  • Roberts SK, Kemp W. Salvage therapies for autoimmune hepatitis: a critical review. Semin Liv Dis. 2017;37:343–362.
  • Selvarajah V, Montano-Loza AJ, Czaja AJ. Systematic review: managing suboptimal treatment responses in autoimmune hepatitis with conventional and nonstandard drugs. Aliment Pharmacol Ther. 2012;36(8):691–707.
  • Czaja AJ. Safety issues in the management of autoimmune hepatitis. Expert Opin Drug Saf. 2008;7(3):319–333.
  • Roberts SK, Lim RT, Strasser S, et al. Efficacy and safety of mycophenolate mofetil in patients with autoimmune hepatitis and suboptimal outcomes after standard therapy. Clin Gastroenterol Hepatol. 2018;16(2):268–277.
  • Efe C, Hagstrom H, Ytting H, et al. Efficacy and safety of mycophenolate mofetil and tacrolimus as second-line therapy for patients with autoimmune hepatitis. Clin Gastroenterol Hepatol. 2017;15(12):1950–1956.
  • Bellentani S, Tiribelli C, Saccoccio G, et al. Prevalence of chronic liver disease in the general population of northern Italy: the Dionysos study. Hepatology. 1994;20(6):1442–1449.
  • Aqel BA, Machicao V, Rosser B, et al. Efficacy of tacrolimus in the treatment of steroid refractory autoimmune hepatitis. J Clin Gastroenterol. 2004;38(9):805–809.
  • Chatur NR, Bain VG, Ma MM, et al. Transplant immunosuppressive agents in non-transplant chronic autoimmune hepatitis: the Canadian association for the study of liver (CASL) experience with mycophenolate and tacrolimus. Liver Int. 2005;25(4):723–727.
  • Larsen FS, Vainer B, Eefsen M, et al. B. Low-dose tacrolimus ameliorates liver inflammation and fibrosis in steroid refractory autoimmune hepatitis. World J Gastroenterol. 2007;13(23):3232–3236.
  • Tannous MM, Cheng J, Muniyappa K, et al. Use of tacrolimus in the treatment of autoimmune hepatitis: a single centre experience. Aliment Pharmacol Ther. 2011;34:394–407.
  • Than NN, Wiegard C, Weiler-Normann C, et al. Long-term follow-up of patients with difficult to treat type 1 autoimmune hepatitis on tacrolimus therapy. Scand J Gastroenterol. 2016;51(3):329–336.
  • Al Taii H, Hanouneh MA, Hanouneh I, et al. The use of tacrolimus in refractory autoimmune hepatitis in children and adults: a single center experience. Scand J Gastroenterol. 2017;52(2):157–158.
  • Pape S, Nevens F, Verslype C, et al. Profiling the patient with autoimmune hepatitis on calcineurin inhibitors: a real-world experience. Eur J Gastroenterol Hepatol. 2020;32(6):727–732.
  • Mistilis SP, Vickers CR, Darroch MH, et al. Cyclosporin, a new treatment for autoimmune chronic active hepatitis. Med J Aust. 1985;143(10):463–465.
  • Hyams JS, Ballow M, Leichtner AM. Cyclosporine treatment of autoimmune chronic active hepatitis. Gastroenterology. 1987;93(4):890–893.
  • Person JL, McHutchison JG, Fong TL, et al. A case of cyclosporine-sensitive, steroid-resistant, autoimmune chronic active hepatitis. J Clin Gastroenterol. 1993;17(4):317–320.
  • Sherman KE, Narkewicz M, Pinto PC. Cyclosporine in the management of corticosteroid-resistant type I autoimmune chronic active hepatitis. J Hepatol. 1994;21(6):1040–1047.
  • Senturk H. Treatment of corticosteroid-azathioprine resistant autoimmune hepatitis with cyclosporin A. Indian J Gastroenterol. 1995;14(3):110–111.
  • Jackson LD, Song E. Cyclosporin in the treatment of corticosteroid resistant autoimmune chronic active hepatitis. Gut. 1995;36(3):459–461.
  • Fernandes NF, Redeker AG, Vierling JM, et al. Cyclosporine therapy in patients with steroid resistant autoimmune hepatitis. Am J Gastroenterol. 1999;94(1):241–248.
  • Malekzadeh R, Nasseri-Moghaddam S, Kaviani MJ, et al. Cyclosporin A is a promising alternative to corticosteroids in autoimmune hepatitis. Dig Dis Sci. 2001;46(6):1321–1327.
  • De Lemos-Bonotto M, Valle-Tovo C, Costabeber AM, et al. A systematic review and meta-analysis of second-line immunosuppressants for autoimmune hepatitis treatment. Eur J Gastroenterol Hepatol. 2018;30(2):212–216.
  • Nicoll AJ, Roberts SK, Lim R, et al. Beneficial response to mycophenolate mofetil by patients with autoimmune hepatitis who have failed standard therapy is predicted by older age and lower immunoglobulin G and INR levels. Aliment Pharmacol Ther. 2019;49(10):1314–1322.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.